Anti-neutrophil cytoplasmic antibody-associated vasculitis: Research & Drug Discovery Data

Drug discovery

drugs

With orphan designations

Overview

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) encompasses rare autoimmune disorders (granulomatosis with polyangiitis [GPA], microscopic polyangiitis [MPA], eosinophilic granulomatosis with polyangiitis [EGPA]) characterized by necrotizing inflammation of small-to-medium vessels. ANCAs targeting PR3 or MPO trigger neutrophil activation, leading to organ damage (e.g., kidneys, lungs). Diagnosis hinges on clinical features, ANCA testing, and histopathology. Treatment involves glucocorticoids combined with cyclophosphamide or rituximab for induction, followed by maintenance therapy. Emerging biologics (e.g., avacopan) aim to reduce glucocorticoid-related toxicity [1][3][6][13]. Relapses and treatment-related adverse effects contribute to morbidity [1][8][14].

Population

Annual incidence: 13–20 cases/million, varying by region (higher in Europe vs. US) [2][9].
MPA predominates in Southern Europe/Japan; GPA more common in Northern Europe [5][9][11].
Onset typically in older adults (except EGPA, linked to younger asthma patients) [4][5].

Burden

1-year survival: ~88%, falling to 72% at 5 years [2][9].
Treatment complications (e.g., infections, malignancies) cause 47% of early deaths [1][14].
Relapses occur in 30–50% of patients, increasing healthcare costs by 2–3x [9][14].

Therapies

Induction: High-dose glucocorticoids + rituximab/cyclophosphamide; plasma exchange for severe renal involvement [1][3][13].
Maintenance: Rituximab/azathioprine/methotrexate for ≥24 months; extended therapy for high-risk relapses [3][8][13].
Emerging therapies: Avacopan (complement C5a inhibitor) for glucocorticoid-sparing effects; mepolizumab for refractory EGPA [5][8][18].

Categories: rare circulatory system diseases, rare respiratory diseases, rare systemic and rheumatological diseases, rare systemic or rheumatologic diseases of childhood, rare transplant-related disorders

Research Papers

1,803 drug discovery papers related to Anti-neutrophil cytoplasmic antibody-associated vasculitis, with 5 first-in-class and 5 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-07-09 | Complement System Inhibitors in Nephrology: A Comprehensive Review.

Background. The complement system plays a critical role in the pathogenesis of several kidney diseases. Dysregulation of complement activation, particularly of the alternative pathway, leads to kidney injury via thrombotic microangiopathy, immune complex deposition, and direct podocyte damage. Summary. Complement system inhibitors represent a paradigm shift in nephrology therapeutics, offering targeted treatment for diseases previously associated with poor outcomes. This review comprehensively examines the present landscape of complement inhibition in kidney disease, including established therapies and emerging agents. Terminal complement inhibitors (eculizumab and ravulizumab) have revolutionized the treatment of atypical haemolytic uremic syndrome, demonstrating remarkable improvements in renal outcomes and survival. Proximal pathway inhibitors targeting Factor B (Iptacopan) and C3 (pegcetacoplan) show promise in C3 glomerulopathy and IgA nephropathy, with recent phase 3 trials demonstrating significant proteinuria reduction. Additional applications include immune complex membranoproliferative glomerulonephritis and ANCA-associated vasculitis, in which complement activation contributes to disease pathogenesis. However, these agents present unique challenges, including infection risk, particularly meningococcal disease, cost considerations, and uncertainty regarding optimal treatment duration.

Open article ↗

2026-07-07 | Metabolic determinants of autoimmune kidney diseases.

Autoantibody-driven autoimmune diseases, such as systemic lupus erythematosus, frequently affect organs such as the kidney. The differentiation and function of pathogenic immune cells that drive these diseases are in part controlled by their metabolic programming. For diseases that affect the kidney, the response of kidney cells to immune-mediated injury is also in part controlled by metabolic changes. Immune cells that promote the production of autoantibodies and/or infiltrate the kidney in lupus nephritis are sustained by enhanced glycolysis and mitochondrial oxidation. These metabolic processes are also enhanced in the mesangial and glomerular endothelial cells of patients with lupus nephritis and animal models of lupus nephritis, which may contribute to tissue injury. Similar alterations in metabolic processes might be involved in other autoimmune diseases that affect the kidney, including IgA nephropathy and ANCA-associated vasculitis. Insights into metabolic changes that occur in the context of autoimmune-mediated kidney diseases might have therapeutic implications. Despite the complexity of metabolic alterations presented by specific immune and renal cells in these autoimmune diseases, targeting of glycolysis, mitochondrial oxidation or iron metabolism could offer novel opportunities to enhance existing treatments for autoimmune-mediated kidney injury.

Open article ↗

2026-07-09 | Complement System Inhibitors in Nephrology: A Comprehensive Review.

Open article ↗

2026-07-07 | Metabolic determinants of autoimmune kidney diseases.

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

4 orphan drug designations for Anti-neutrophil cytoplasmic antibody-associated vasculitis, including 2 approved therapies.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
a humanized IgG4 mAb that binds to hC5aR1 and blocks C5a binding to C5aR1 resulting in inhibition of C5aR1 activation and downstream signaling	antibodies	FDA	2026-02-19	—	Otsuka Pharmaceutical Development & Commercialization, Inc
Gabexate	small molecules	FDA	2020-09-18	—	RNR BioMedical Inc.
avacopan [Tavneos]	small molecules	FDA	2014-06-02	2021-10-07	ChemoCentryx, Inc.
rituximab [Rituxan]	antibodies	FDA	2006-02-14	2011-04-19	Genentech, Inc.

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Overview

Population

Burden

Therapies

Categories: rare circulatory system diseases, rare respiratory diseases, rare systemic and rheumatological diseases, rare systemic or rheumatologic diseases of childhood, rare transplant-related disorders

Research Papers

2026-07-09 | Complement System Inhibitors in Nephrology: A Comprehensive Review.

2026-07-07 | Metabolic determinants of autoimmune kidney diseases.

2026-07-09 | Complement System Inhibitors in Nephrology: A Comprehensive Review.

2026-07-07 | Metabolic determinants of autoimmune kidney diseases.

Drug Discovery Landscape

Updated: Jul 30, 2026